INFORMATION BY CANCER TYPE

Lymphoma

FDA Grants Imbruvica an Accelerated Approval for Marginal Zone Lymphoma
Imbruvica was granted an accelerated FDA approval to treat some patients with marginal zone lymphoma (MZL). 
Pivotal Trial Finds That Imbruvica Shows Benefit in CLL and SLL
BY Danielle Bucco
Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.
What's In Store for Hematologic Malignancies?
BY Gina Columbus and Ellie Leick
Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.
Transplant Is a Mainstay in Hematologic Cancers, Expert Says
BY Gina Columbus
Stem cell transplant is still the only curative treatment option for many hematologic malignancies, even as novel drugs continue to emerge. 
Patients With Cancer and Their Providers Share Stories of Hope
BY Katie Kosko
Patients and providers shared inspiring stories of hope, as well as some tips for better living at the Seventh Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer. 
Keytruda Granted Priority Review for Hodgkin Lymphoma
BY Jason M. Broderick
Keytruda was granted a priority review to a supplemental biologics license application (sBLA) to treat a subset of patients with classical Hodgkin lymphoma.
Immunotherapy Strategies Emerging in Lymphoma
BY Lauren M. Green
While Opdivo is currently the only immunotherapy agent approved for Hodgkin lymphoma, immunotherapy strategies are beginning to emerge in other indications in the field.
Looking Ahead in T-Cell Lymphoma
BY Gina Columbus
CURE spoke with an expert on the importance of classifying T-cell lymphomas and what is next in this field.
Expert Discusses Exploring Alternative Treatments for Large Cell Lymphoma
BY Gina Columbus
Patients with activated B-cell-like lymphoma may not respond to standard treatment, so new options are being explored.
Opdivo Shows Benefit in Classical Hodgkin Lymphoma
BY Jason M. Broderick
Updated trial data shows that Opdivo had a high objective response rate for a cohort of patients with classical Hodgkin Lymphoma.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Lymphoma CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma.
AIDS-Related Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.
Childhood Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.
Primary CNS Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of primary CNS lymphoma.